doravirine/TDF/3TC FDC (Delstrigo)

Delstrigo is a light yellow tablet embossed with “776” on one side. (Source: aidsinfo.nih)


Delstrigo was approved in the US in August 2018 and in Europe in November 2018.

  • Delstrigo is a Fixed Dose Combination (FDC) containing 100 mg doravirine plus 300 mg lamivudine (3TC) plus 300 mg tenofovir DF.
  • It is approved in the US for people who are using HIV treatment for the first time and who do not have resistance to any of these drugs.
  • Delstrigo can be taken with or without food.
  • Side effects are similar to the individual drugs – see doravirine, lamivudine and tenofovir DF.
  • These include nausea and headache in up to one in ten people but also involves monitoring kidney function and bone health (linked to tenofovir DF).
  • Drug interactions (linked to doravirine) include, but are not limited to:
    • Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin.
    • Androgen receptor inhibitor: enzalutamide.
    • Antimycobacterials: rifampin, rifapentine.
    • Mitotane.
    • St. John’s wort (Hypericum perforatum).
  • Delstrigo is manufactured by Merck (MSD).
  • For full details please see the full prescribing information.

Further information

The European patient information and detailed Product Information for Delstrigo are available from this link at the European Medicines Agency (EMA) website.

The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.

The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.